Cue Biopharma, a clinical-stage biopharmaceutical company, announced a $50 million private placement by selling 1.4 million shares and pre-funded warrants to accredited investors at about $33.21 per share. The funding, led by Cormorant Asset Management and including Columbia Threadneedle Investments, will support Cue's clinical development and general corporate needs. The company is advancing therapies targeting functional cures for immunological disorders, with upcoming clinical data expected by Q3 2026. The private placement is expected to close around July 13, 2026, subject to customary conditions.
BlackRock reported a strong third quarter with adjusted earnings of $15.93 per share, beating estimates by a wide margin and marking a 38% increase year-over-year. Revenue grew 19% to $7.75 billion, driven by $205 billion in net client inflows, inclu...
Home BancShares will release its Q3 2026 earnings report on October 14, with analysts expecting earnings per share of $0.64 and revenue around $293-$294 million, marking a 5.5% revenue increase and 4.9% EPS growth from last year. The bank's P/E ratio...
Hyperion Materials & Technologies has acquired The Ultra-Met Company, a tungsten carbide manufacturer based in Urbana, Ohio, to expand its capabilities in serving the US aerospace and defense sectors. Ultra-Met works closely with the US Department of...
Morgan Stanley reported Q3 earnings per share of $3.03, surpassing analyst estimates of $2.93 and $2.83 consensus. Revenue reached $20.34 billion, a 12% increase year-over-year and above the $19.93 billion estimate. Strong equity trading and record w...
Bank of New York Mellon is set to report its Q3 2026 earnings, with analysts expecting earnings per share of $2.27 and revenue of $5.55 billion. This represents an 18.3% increase in earnings and a 9.5% rise in revenue compared to the previous year, d...
